Clinical trial
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)…
NCT00001586 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001586 |
|---|---|
| Title | Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis |
| Official title | Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug, Other |
| Interventions | Rituximab, Fludarabine phosphate, Leukemic or stroma cells |
| Enrollment | 105 |
| Start date | Sep 1, 1997 |
| Primary completion | Nov 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | Nov 4, 1999 |
| Last update posted | May 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: